Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300468 | 1.00 | FKBP1A (0.48) | FKBP1ACASP1CASP3CASP8FABP7 | |
| SCHEMBL1300466 | 1.00 | FKBP1A (0.48) | FKBP1ACASP1CASP3CASP8FABP7 | |
| SCHEMBL9609008 | 0.89 | FKBP1A (0.48) | FKBP1ACASP1FABP7FABP5HPGD | |
| SCHEMBL12109076 | 0.86 | FKBP1A (0.46) | FKBP1ACYP2C19SMN1; SMN2ELANE | |
| SCHEMBL12898945 | 0.86 | FKBP1A (0.48) | FKBP1ACASP1HPGDELANE | |
| SCHEMBL30527653 | 0.85 | FKBP1A (0.60) | FKBP1ACASP1 | |
| SCHEMBL31384865 | 0.83 | FKBP1A (0.50) | FKBP1ACASP1 | |
| SCHEMBL31384867 | 0.80 | FKBP1A (0.45) | FKBP1ACASP1HPGDELANE | |
| SCHEMBL31384899 | 0.80 | FKBP1A (0.45) | FKBP1ACASP1ELANE | |
| SCHEMBL25408533 | 0.79 | FKBP1A (0.51) | FKBP1ACYP2C19SMN1; SMN2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | FKBP1A 617/4885CASP1 4516/4885CASP3 4773/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | FKBP1A 617/4885CASP1 4516/4885CASP3 4773/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | FKBP1A 617/4885CASP1 4516/4885CASP3 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.